Article
IDH1 Mutation Increases the Sensitivity of Glioma Organoids to Radiotherapy and Targeted Therapy.
Current medicinal chemistry - 1 Jan 2026
Yang Chenxuan, Li Meilin, Wu Dongdong, Xu Bainan
Abstract excerpt
INTRODUCTION: In gliomas, the Isocitrate Dehydrogenase (IDH1) mutation is a key molecular marker that can distinguish subtypes. IDH1-mutant gliomas grow more slowly, are sensitive to radiotherapy and chemotherapy, and have a better prognosis. However, there are still individual differences in treatment responses and prognosis among patients with this subtype, making traditional treatments difficult to adapt....
Read the complete abstract on PubMedTopics
- Isocitrate Dehydrogenase
- Glioma
- Humans
- Organoids
- Mutation
- Antineoplastic Agents
- Brain Neoplasms